High throughput genetic screening in Hungarian patients with definite or suspected LQTS identified putative disease-causing mutations in 53% of cases, demonstrating significant genetic heterogeneity.
Answers are grounded in this paper and cite their sources.
May inform targeted screening in Hungarian LQTS patients; leaves open broader validation and generalizability.
E-mail: lidiahategan@yahoo.com The long QT syndrome (LQTS) is a disease of the cardiac ion channels with a heterogeneous genetic background. Although case reports describing mutations in known LQTS genes in Hungarian LQTS patients are available, the distribution of the disease causing genes in a larger cohort of Hungarian LQTS patients is still unknown. Our goal was to screen all LQTS causing disease genes in a cohort of Hungarian patients with definite or suspected LQTS for presence of mutations. Thirty-six patients (12 males, 24 females, median age 40±15 years) were screened. The patients had either a definite diagnosis of LQTS, based on prolonged QTc interval on their resting ECG (n=23), developed QTc prolongation on pharmacological provocation (n=5), or were survivors of sudden cardiac death in whom the suspicion of LQTS had been raised (n=8). All of the 13 genes, known to cause LQTS, were sequenced. A putative disease causing mutation was defined as a nucleotide variant which was either novel, or had a minor allele frequency less than 0.5% according to the published databases. Among the 36 patients, a putative disease causing mutation was identified in 19 patients (53%). Twentyfour mutations were found in 19 patients: 14 patients had single mutations and 5 patients had compound mutations in two different genes. The three major LQTS genes made up the majority of the identified mutations as KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3) mutations were identified in 17%; 21% and 8% of the cases, respectively. The distribution for mutations in rare LQTS genes were as follows: ANK2 (LQT4): 13%; KCNE1 (LQT5): 4%; KCNE2 (LQT6): 4%; KCNJ2 (LQT7): 13%; CACNA1C (LQT8): 4%; AKAP9 (LQT11): 13%; STNA1 (LQT12): 4%. The results of our large-scale genetic screening provide the first available data for disease gene distribution in Hungarian patients with LQTS. It also highlights the genetic heterogeneity of LQTS and demonstrates that gene-negative patients are not infrequent.
No takes yet. Share an insight, caveat, or question.
Hategan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: